New practice-changing research will reduce the need for major surgery in many melanoma patients
9 June 2017
New findings from a large international clinical trial published in the New England Journal of Medicine this week are likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost. Many Australian patients participated in this trial, and Melanoma Institute Australia was the top recruiting centre in the world.
National and international melanoma management guidelines currently state that patients who are found to have melanoma deposits in a “sentinel” lymph node should undergo immediate completion lymph node clearance — a large operation that removes all remaining lymph nodes in the area (the axilla, the groin or the neck).
However, the initial results of the second Multicenter Selective Lymphadenectomy Trial (MSLT-II) indicate that there is no difference in survival for sentinel-node positive patients who undergo immediate lymph node clearance compared to those who are closely monitored with ultrasound to detect disease progression. The three-year melanoma-specific survival was 86±1.3% in 824 patients who had a completion lymph node dissection versus 86±1.2% in 931 patients who were monitored, after a median follow up of 43 months.
“These results are going to change treatment recommendations for sentinel-node positive patients, most of whom will avoid the short-term and long-term morbidity that may follow a complete lymph node dissection,” said co-author and Senior Surgeon at Melanoma Institute Australia, Professor John Thompson AO. “Only those who are found to have disease in their lymph nodes during the course of follow-up — about 20% — will ultimately require full regional lymph node dissection. This change in treatment recommendation is likely to improve the quality of life for many patients around the world.” In particular, this will make a big difference to patients who have disease of the lower limb, by reducing the rate of a common complication, lymphoedema.
Although immediate lymph node clearance in sentinel-node positive patients will no longer be recommended, an initial sentinel lymph node biopsy — a minor procedure able to be performed at the same time as wide excision of the primary melanoma site — will still be required to provide accurate staging and guide treatment planning, as well as to provide a reliable estimate of prognosis.
Although no significant survival benefit was achieved by immediate completion lymph node dissection, the authors noted that the procedure did provide some potential benefits for patients with melanoma, including improved staging which can help identify high-risk patients. As well, it provides information that may be required for inclusion in medical oncology clinical trials of new medical therapies, and improves regional disease control.
“The management of regional lymph nodes has long been controversial in the treatment of many solid tumours, particularly melanoma,” noted Professor Thompson. “But this trial provides robust evidence to change the current practice guidelines to improve our management of patients with melanoma.”
Publication: Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017; 376:2211-2222
The inspiring story of Emma Betts premieres on Australian Story
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Toyota helps tackle Australia's national cancer - melanoma
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Tackling the Kokoda Trail for melanoma
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Professor Richard Scolyer presents at world's largest annual meeting of pathologists
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.
Farewell from Carole Renouf, CEO of Melanoma Institute Australia
A message from our CEO, Carole Renouf
Marching in the twilight
Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma.
Researchers uncover treatment sequence for advanced melanoma patients
Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.
An unsung hero of melanoma care for nearly 30 years
Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.
Sharing our research on melanoma surgery
MIA is sharing it's research with the global surgical oncology community this week at the Society of Surgical Oncology Annual Cancer Symposium.
14 Melanoma Marches down, 7 to go!
It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.
Melanoma March keeps marching
Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.
Melanoma March kicks off for 2018
Melanoma Institute Australia's annual fundraising initiative is all systems go!
Calls for urgent crackdown on illegal backyard solariums
The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.
15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma
15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate.
Excision margins for melanoma redefined
Updated guidelines defining appropriate excision margins have been published thanks to research from MIA.
A Pawsome Story of Hope
Joanne and her trusty companion Frankie spend their days spreading a message of hope in hospitals, nursing homes, even prisons. It is a long way from her darkest hour facing palliative care. This is her story of hope.
A new generation of melanoma researchers
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.
Prestigious award in pathology for Professor Scolyer
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.